IDDI appoints Dr. Jean-Pierre Bizzari as a new Board Member
IDDI is delighted to announce the appointment of Jean-Pierre Bizzari, MD, as a new Board Member.
Dr. Bizzari brings 35 years of industry experience in oncology drug development with major contribution to the approval of multiple leading anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® (CPT-11).

Jean-Pierre Bizzari joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). He then joined Rhône-Poulenc Rorer in 1993 as Vice President of Clinical Oncology, based in Paris and moved to Collegeville (PA – USA) in 1997. From 2002 tol 2008, Mr. Bizzari served as Vice President of Clinical Oncology Development at Sanofi-Aventis in Malvern, PA before joining Celgene.
We are honored to welcome Dr. Bizzari to our Board. His extensive experience in the pharmaceutical industry will be highly valuable for the strategic development of IDDI.